Hansoh Pharma’s Ameile Achieves Key Trial Success
Company Announcements

Hansoh Pharma’s Ameile Achieves Key Trial Success

Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.

Hansoh Pharmaceutical Group has announced successful results from its Phase III trial of Ameile, an innovative drug designed to treat EGFR-mutated non-small cell lung cancer, in combination with chemotherapy. The trial demonstrated a significant improvement in progression-free survival for patients, marking an important milestone for the company. Detailed results are set to be presented at an upcoming medical conference.

For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App